Physician profile
Kamran Farrukh
NPI 1760447205
$7,949.49
in general payments reported to CMS, 2019-2025
53 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $712 · 2021: $1,454 · 2022: $1,086 · 2023: $1,264 · 2024: $1,555 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,529.51 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $635.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $593.38 | 2020-2025 | |
| Lilly USA, LLC | $506.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $465.11 | 2019-2025 | |
| Amgen INC. | $414.92 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $391.63 | 2019-2025 | Spravato |
| Abbott Laboratories | $306.81 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $254.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.81 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $245.05 | 2022-2025 | |
| Astellas Pharma US INC | $195.91 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $173.43 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $169.36 | 2024-2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.78 | 2023-2025 | Caplyta |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Farrukh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.